Friday, July 10, 2026
🇺🇸 FDA

pharma · Lymphoma of B-cell origin · Malignant Solid Tumors

Genmab

Genmab A/S

Genmab trial registry — 29 ClinicalTrials.gov studies with program phase, status, and indication context.

Website Investor relations
Carl Jacobsens Vej 30, 2500 Valby, DK HQ
2,847 Employees
EMA registrant Type
Company details
Status
Public
HQ
Carl Jacobsens Vej 30, 2500 Valby, DK
Employees
2,847
Programs
29
Drugs
56
Patents
0
Official website ↗ All projects Drug pipeline News & analysis
Intelligence · Clinical Trials

Genmab clinical trials

Registry index of 29 ClinicalTrials.gov studies linked to Genmab programs — each row shows trial ID, program name, phase, status, and indication.

Genmab trial registry — 29 ClinicalTrials.gov studies with program phase, status, and indication context.

Recent trial activity

8 updates

Latest clinical program signals indexed for Genmab.

  1. GCT3014-01 — Phase 2

    Clinical update

  2. GCT1079-01 — Phase 1

    Clinical update

  3. GCT1057-01 — Phase 1

    Clinical update

  4. GCT1056-01 — Phase 1

    Clinical update

  5. GCT1046-07 — Phase 2

    Clinical update

  6. GCT1046-04 — Phase 2

    Clinical update

  7. GCT3013-05 — Phase 3

    Clinical update

  8. GCT3013-03 — Phase 2

    Clinical update

Trial registry

29 studies
  8. 2023-508526-10-00

    GCT1042-01

    Phase 2 active small_molecule

    Malignant solid tumors: Patients with relapsed or refractory, advanced and/or metastatic melanoma, Non-Small Cell Lung Cancer (NSCLC), Head and neck squamous cell carcinoma (HNSCC), Panctreatic ductal adenocarcinoma (PDAC) or Colorectal Cancer (CRC).

    CTIS ↗
  11. 2023-509059-15-00

    GCT1046-01

    Phase 2 active small_molecule

    Malignant solid tumors: endometrial carcinoma (EC), urothelial carcinoma (UC), triple-negative breast cancer (TNBC), squamous cell carcinoma of the head and neck (SCCHN), or cervical cancer.

    CTIS ↗
  20. 2025-520468-16-00

    GCT1046-07

    Phase 2 active small_molecule

    Cutaneous Melanoma, Relapsed/Refractory, Locally Advanced Unresectable Melanoma (Stage IIIB, IIIC, or IIID), Metastatic Cutaneous Melanoma (Stage IV)

    CTIS ↗

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.